Sfoglia per Rivista
Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.
2006-01-01 De Franceschi L;Daraio F;Filippini A;Carturan S;Muchitsch EM;Roetto A;Camaschella C
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
2009-01-01 Bruno B; Sorasio R; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Festuccia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Ciccone G; Boccadoro M
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
2019-01-01 Maffini E.; Storer B.E.; Sandmaier B.M.; Bruno B.; Sahebi F.; Shizuru J.A.; Chauncey T.R.; Hari P.; Lange T.; Pulsipher M.A.; McSweeney P.A.; Holmberg L.; Becker P.S.; Green D.J.; Mielcarek M.; Maloney D.G.; Storb R.
LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
2017-01-01 Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I; Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients
2020-01-01 Baron F.; Efficace F.; Cannella L.; Willemze R.; Vignetti M.; Muus P.; Marie J.-P.; Ferrero D.; Fazi P.; Sala E.L.; Bourhis J.-H.; Fabbiano F.; Bosi A.; Sborgia M.; Martinelli G.; Wittnebel S.; Trisolini S.; Petti M.C.; Halkes C.J.M.; van der Velden W.J.F.M.; de Witte T.; Amadori S.; Zittoun R.A.; Suciu S.
Long-term molecular responses to imatinib inpatients with chronic myeloid leukemia: comparison between complete cytogeneticresponders treated in early and in late chronic phase.
2007-01-01 Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia
2015-01-01 Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; D'Adda, M; Stagno, F; Tiribelli, M; Salvucci, M; Fava, C; Martino, B; Cedrone, M; Bocchia, M; Trabacchi, E; Cavazzini, F; Usala, E; Russo Rossi, A; Bochicchio, Mt; Soverini, S; Alimena, G; Cavo, M; Pane, F; Martinelli, G; Saglio, G; Baccarani, M; Rosti, G
Loss of surface HLA class I molecules in leukemic myeloblasts is correlated with an increased leukocyte concentration at onset.
1992-01-01 SAVOIA P ;D'ALFONSO S ;PERUCCIO D ;ISABELLA N ;FALDA M ;RESEGOTTI L ;RICHIARDI P
Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
2007-01-01 BERNENGO MG; QUAGLINO P; COMESSATTI A; ORTONCELLI M; NOVELLI M; LISA F; FIERRO MT
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.
2001-01-01 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M
M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia.
1992-01-01 ZACCARIA A ;MARTINELLI G ;BUZZI M ;ZUFFA E ;ZAMAGNI MD ;TESTONI N ;RUSSO D ;GUERRASIO A ;SAGLIO G ;TURA S
MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse.
1990-01-01 Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A.
MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)
2015-01-01 Scarfo, L; Quaresmini, G; Mauro, Fr; Orlandi, E; Reda, G; Laurenti, L; Coscia, M; Ambrosetti, A; Murru, R; Trentin, L; Guelill, A; Visco, C; Morabito, F; Frustaci, A; Ciolli, S; Rossini, F; Cuneo, A; Gozzetti, A; Scortechini, I; Pane, F; Zinzani, Pl; Ferrara, F; Mannina, D; Marasca, R; Pierri, I; Specchia, G; Chiarenza, A; Zallio, F; Molica, S; De Paoli, L; Torreggiani, A; Brugiatelli, M; Semenzato, G; Innocenti, I; Picardi, P; Pizzolo, G; Foa, R; Rambaldi, A; Ghia, P
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
2004-01-01 Barosi, G; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Tosi, P; Tura, S; Palumbo, A
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
2006-01-01 BAROSI G; CARELLA A; LAZZARINO M; MARCHETTI M; MARTELLI M; RAMBALDI A; TARELLA C; VITOLO U; ZINZANI PL; TURA S
Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation
2005-01-01 BAROSI G; CARELLA A; LAZZARINO M; MARCHETTI M; MARTELLI M; RAMBALDI A; TARELLA C; VITOLO U; ZINZANI PL; TURA S
Marriage and parenthood among subjects cured of childhood cancer: a report from the Italian AIEOP Off-Therapy Registry
2011-01-01 Pivetta E; Maule MM; Pisani P; Zugna D; Haupt R; Jankovic M; Arico' M; Casale F; Clerico A; Cordero di Montezemolo L; Kiren V; Locatelli F; Palumbo G; Pession A; Pillon M; Santoro N; Terenziani M; Valsecchi MG; Dama E; Magnani C; Merletti F; Pastore G.
Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway.
2014-01-01 P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia.
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
2010-01-01 Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA.
MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III.
2011-01-01 Cavallo F; Lupo B; Di Raimondo F; Ben Yehuda D; Corradini P; Patriarca F; Cavo M; Carella AM; Omedè P; Stanevsky S;Siniscalchi A; Cavalli M; Marcatti M; Petrò D; Crippa C; Levi A; Caravita Di Toritto T; Nagler A; Boccadoro M; Palumbo A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. | 2006 | De Franceschi L;Daraio F;Filippini A;Carturan S;Muchitsch EM;Roetto A;Camaschella C | |
| LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA | 2009 | Bruno B; Sorasio R; Patriarca F; Mordini N; Allione B; Carnevale-Schianca F; Giaccone L; Festuccia M; Aglietta M; Levis A; Gallamini A; Fanin R; Palumbo A; Ciccone G; Boccadoro M | |
| Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma | 2019 | Maffini E.; Storer B.E.; Sandmaier B.M.; Bruno B.; Sahebi F.; Shizuru J.A.; Chauncey T.R.; Hari P.; Lange T.; Pulsipher M.A.; McSweeney P.A.; Holmberg L.; Becker P.S.; Green D.J.; Mielcarek M.; Maloney D.G.; Storb R. | |
| LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE | 2017 | Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I; Crugnola, M; Latagliata, R; Breccia, M; Ferrero, D; Trawinska, MM; Castagnetti, F; Annunziata, M; Stagno, F; Tiribelli, M; Binotto, G; Fava, C; Crisa, E; Mansueto, G; Gozzini, A; Falzetti, F; Montefusco, E; Iurlo, A; Russo, S; Cedrone, M; Rossi, AR; Gugliotta, G; Pregno, P; Isidori, A; Mauro, E; Atelda, R; Giglio, G; Celesti, F; Sora, F; Storti, S; D'Addosio, AM; Galimberti, S; Orlandi, E; Calistri, E; Bocchia, M; Cavazzini, F; Cambrin, GR; Luciano, L; Abruzzese, E; Capodanno, I | |
| Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients | 2020 | Baron F.; Efficace F.; Cannella L.; Willemze R.; Vignetti M.; Muus P.; Marie J.-P.; Ferrero D.; Fazi P.; Sala E.L.; Bourhis J.-H.; Fabbiano F.; Bosi A.; Sborgia M.; Martinelli G.; Wittnebel S.; Trisolini S.; Petti M.C.; Halkes C.J.M.; van der Velden W.J.F.M.; de Witte T.; Amadori S.; Zittoun R.A.; Suciu S. | |
| Long-term molecular responses to imatinib inpatients with chronic myeloid leukemia: comparison between complete cytogeneticresponders treated in early and in late chronic phase. | 2007 | Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML. | |
| Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia | 2015 | Gugliotta, G; Castagnetti, F; Breccia, M; Levato, L; D'Adda, M; Stagno, F; Tiribelli, M; Salvucci, M; Fava, C; Martino, B; Cedrone, M; Bocchia, M; Trabacchi, E; Cavazzini, F; Usala, E; Russo Rossi, A; Bochicchio, Mt; Soverini, S; Alimena, G; Cavo, M; Pane, F; Martinelli, G; Saglio, G; Baccarani, M; Rosti, G | |
| Loss of surface HLA class I molecules in leukemic myeloblasts is correlated with an increased leukocyte concentration at onset. | 1992 | SAVOIA P ;D'ALFONSO S ;PERUCCIO D ;ISABELLA N ;FALDA M ;RESEGOTTI L ;RICHIARDI P | |
| Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. | 2007 | BERNENGO MG; QUAGLINO P; COMESSATTI A; ORTONCELLI M; NOVELLI M; LISA F; FIERRO MT | |
| Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. | 2001 | Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M | |
| M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. | 1992 | ZACCARIA A ;MARTINELLI G ;BUZZI M ;ZUFFA E ;ZAMAGNI MD ;TESTONI N ;RUSSO D ;GUERRASIO A ;SAGLIO G ;TURA S | |
| MACOP-B treatment for intermediate and high-grade non-Hodgkin's lymphomas at diagnosis and in relapse. | 1990 | Tarella C; Gallo E; Ferrero D; Badoni R; Carlesso N; Caracciolo D; Pileri A. | |
| MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY) | 2015 | Scarfo, L; Quaresmini, G; Mauro, Fr; Orlandi, E; Reda, G; Laurenti, L; Coscia, M; Ambrosetti, A; Murru, R; Trentin, L; Guelill, A; Visco, C; Morabito, F; Frustaci, A; Ciolli, S; Rossini, F; Cuneo, A; Gozzetti, A; Scortechini, I; Pane, F; Zinzani, Pl; Ferrara, F; Mannina, D; Marasca, R; Pierri, I; Specchia, G; Chiarenza, A; Zallio, F; Molica, S; De Paoli, L; Torreggiani, A; Brugiatelli, M; Semenzato, G; Innocenti, I; Picardi, P; Pizzolo, G; Foa, R; Rambaldi, A; Ghia, P | |
| Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) | 2004 | Barosi, G; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Tosi, P; Tura, S; Palumbo, A | |
| Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation | 2006 | BAROSI G; CARELLA A; LAZZARINO M; MARCHETTI M; MARTELLI M; RAMBALDI A; TARELLA C; VITOLO U; ZINZANI PL; TURA S | |
| Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation | 2005 | BAROSI G; CARELLA A; LAZZARINO M; MARCHETTI M; MARTELLI M; RAMBALDI A; TARELLA C; VITOLO U; ZINZANI PL; TURA S | |
| Marriage and parenthood among subjects cured of childhood cancer: a report from the Italian AIEOP Off-Therapy Registry | 2011 | Pivetta E; Maule MM; Pisani P; Zugna D; Haupt R; Jankovic M; Arico' M; Casale F; Clerico A; Cordero di Montezemolo L; Kiren V; Locatelli F; Palumbo G; Pession A; Pillon M; Santoro N; Terenziani M; Valsecchi MG; Dama E; Magnani C; Merletti F; Pastore G. | |
| Mechanisms of Vgamma9Vdelta2 T cell activation by soluble metabolites generated by the mevalonate pathway. | 2014 | P. Sciancalepore; B. Castella; J. Kopecka; I. Campia; G. Gelsomino; M. Foglietta; D. Ghigo; M. Boccadoro; C. Riganti; M. Massaia. | |
| Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial | 2010 | Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA. | |
| MELPHALAN/PREDNISONE/LENALIDOMIDE (MPR) VERSO MELPHALAN (200 MG/M2) E TRAPIANTO AUTOLOGO (MEL200) IN PAZIENTI CON NUOVA DIAGNOSI DI MIELOMA MULTIPLO (MM): UNO STUDIO DI FASE III. | 2011 | Cavallo F; Lupo B; Di Raimondo F; Ben Yehuda D; Corradini P; Patriarca F; Cavo M; Carella AM; Omedè P; Stanevsky S;Siniscalchi A; Cavalli M; Marcatti M; Petrò D; Crippa C; Levi A; Caravita Di Toritto T; Nagler A; Boccadoro M; Palumbo A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile